Data thru May 13, 2026
HomeTrendsArticlesDrug MarketsTherapeutic ClassesManufacturersPricingContact
Back to Market Feed

THEOPHYLLINE ER 400 MG TABLET

Theophylline
$0.9123per EA
High Outlier

Strength

400 mg/1

Manufacturer

Rhodes Pharmaceuticals L.P.

NDC

42858070101

Classification

Generic

Dosage Form

TABLET, EXTENDED RELEASE

Route

ORAL

Last Updated

4/22/2026

Active Ingredients

THEOPHYLLINE ANHYDROUS

Approval Type

Generic (ANDA)

FDA Application

ANDA040086

On Market Since

2/2/2012

Pharmacological Classes

Methylxanthine
Xanthines

Price History

1W

0.0%

1M

-12.1%

3M

-4.4%

6M

+4.1%

1Y

+11.5%

3Y

+51.8%

5Y

+24.0%

All

+0.1%

Generic Alternatives

1 alternative • Same active ingredient

THEOPHYLLINE ER 400 MG TABLET
Generic
68462038001•Glenmark Pharmaceuticals Inc., USA
$0.9123

Related Drugs

Same classification

BACK-BODY PAIN 500-32.5 MG CPLT
Generic
70000012702•Cardinal Health
$0.0448
per EA
TENSION HEADACHE CAPLET
Generic
70000015901•Cardinal Health
$0.0579
per EA
TENSION HEADACHE CAPLET
Generic
70000015902•Cardinal Health
$0.0579
per EA
EXTRA PAIN RELIEF CAPLET
Generic
49483037000•Time-Cap Labs Inc.
$0.0621
per EA
QC HEADACHE RELIEF TABLET
Generic
63868048501•Chain Drug Marketing Association
$0.0629
per EA
GS MIGRAINE 250-250-65 MG CPLT
Generic
00113037462•L. Perrigo Company
$0.0668
per EA
GS MIGRAINE 250-250-65 MG CPLT
Generic
00113037478•L. Perrigo Company
$0.0668
per EA
PAIN RELIEVER PLS 250-250-65 MG
Generic
00536132601•Rugby Laboratories
$0.0668
per EA
MIGRAINE 250-250-65 MG CPLT
Generic
24385036571•AmerisourceBergen
$0.0668
per EA
MIGRAINE FORMULA CAPLET
Generic
24385036578•AmerisourceBergen
$0.0668
per EA

Data Source

Pricing data sourced from the National Average Drug Acquisition Cost (NADAC) survey, published by the Centers for Medicare & Medicaid Services (CMS). Updated weekly.

Disclaimer

This site is for informational purposes only and does not constitute medical, pharmaceutical, or financial advice. NADAC prices are survey-based estimates and may not reflect actual acquisition costs at any specific pharmacy.

Navigate

HomeAboutManufacturersDrug MarketsTherapeutic ClassesTrendsArticlesPricingContact

© 2026 NADAC Intelligence. All rights reserved. Not affiliated with CMS or any government agency.

Terms of ServicePrivacy Policy